The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Biosimilars: Unanswered Questions

Biosimilars: Unanswered Questions

July 5, 2016 • By Susan Bernstein

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Debate continues about how biosimilars that are emerging to treat rheumatic diseases will be named and monitored, said panelists at a recent meeting in Washington, D.C.—Biosimilars in the United States: Next Steps.

You Might Also Like
  • Most Rheumatologists Want FDA to Better Regulate Biosimilars
  • Biosimilars to Raise Unique Questions
  • Biosimilars Update: FDA Panel Voted to Approve Biosimilars for Etanercept & Adalimumab at July Meeting
Also By This Author
  • ACR Issues Position Statements on Key Rheumatology Issues

Angus Worthing, MD, FACR, FACP, a member of the ACR’s Government Affairs Committee, shared rheumatologists’ concerns as these new therapies come to market. And it’s an urgent debate: a biosimilar to Remicade (infliximab), called Inflectra (infliximab-dyyb), was approved by the Food and Drug Administration (FDA) on April 5. And two more are on the horizon: The FDA’s Arthritis Advisory Committee met and reviewed proposed biosimilars for etanercept and adalimumab in July, voting unanimously to approve them.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“Right now, we have a lot of confidence that the FDA will give us good information on these products’ safety and efficacy,” said Dr. Worthing. “Full transparency about biosimilars is [needed in order] for everyone to be confident about using these therapies to treat rheumatic diseases. Patients need to know what they’re taking, and physicians need to know what they’re prescribing. This can be accomplished by using distinct names for biosimilars, having clear information on FDA drug labels and implementing consumer-oriented pharmacy dispensing practices.”

Drug Naming & Substitution Concerns
Prescribers still control drug substitution at this point, because no manufacturers have applied for interchangeable status yet. There’s a higher standard of proof involved when the drug is so similar to the reference product that it could be substituted by the pharmacy like generic drugs are, something that concerns rheumatologists, according to Dr. Worthing. Pharmacy notification of biosimilar substitution to prescribers is something rheumatologists strongly support, he said.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“We currently do not know what may happen when switching a patient back and forth between a biosimilar drug and its original reference product,” he continued. Some patients could become immune to the new biosimilar, as well as the original biologic drug, he said. “This may cause the drugs not to work or even cause allergic reactions, which is why it’s incredibly important that we protect patients against forced switching between biologics and biosimilars by insurance companies and pharmacy benefit management companies.”

When a patient’s condition is well controlled or in remission on one agent, changing products may not be in the patient’s best interest.

The FDA Steps In
The FDA has issued draft guidance documents on naming and labeling to gather opinions on future regulations, said panelist Leah Christl, PhD, the FDA’s associate director for therapeutic biologics. It is also investing in professional and patient education campaigns, and has created the Purple Book, an online biosimilars resource for prescribers.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 | Single Page

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: ACR Government Affairs Committee, Biologics & Biosimilars, rheumatic diseases

You Might Also Like:
  • Most Rheumatologists Want FDA to Better Regulate Biosimilars
  • Biosimilars to Raise Unique Questions
  • Biosimilars Update: FDA Panel Voted to Approve Biosimilars for Etanercept & Adalimumab at July Meeting
  • The Science Behind Biosimilars

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)